Figure 5.

PSK combined with docetaxel enhances tumor infiltrating T cells. Mice bearing orthotopic TRAMP-C2 tumors were treated with either: 1) saline; 2) PSK (300 mg/kg daily; 3) docetaxel (5 mg/kg); or 4) PSK and docetaxel. Mice were sacrificed on day 12 after treatment and tumors were harvested. (A) Fluorescent immunohistochemistry was performed for CD4⁺ and CD8⁺ T cells (examples of positive cells indicated by arrows). Populations of both CD4⁺ (B) and CD8⁺ (C) T cell subsets were significantly higher in mice treated with docetaxel and PSK compared to PSK or docetaxel alone (p<0.05).